newsfilter
← Latest News
GlobeNewswire·

Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052

- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF - - PRA052 is the second clinical candidate identified using the Prometheus360™